Vivo Capital LLC Has $237.23 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Vivo Capital LLC grew its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 0.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,060,135 shares of the biotechnology company’s stock after purchasing an additional 13,303 shares during the period. Ascendis Pharma A/S comprises about 22.2% of Vivo Capital LLC’s holdings, making the stock its largest holding. Vivo Capital LLC’s holdings in Ascendis Pharma A/S were worth $237,225,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of ASND. SG Americas Securities LLC lifted its stake in Ascendis Pharma A/S by 12.6% during the first quarter. SG Americas Securities LLC now owns 2,088 shares of the biotechnology company’s stock worth $246,000 after purchasing an additional 234 shares during the last quarter. Comerica Bank bought a new stake in Ascendis Pharma A/S during the first quarter worth about $275,000. Victory Capital Management Inc. lifted its stake in Ascendis Pharma A/S by 1,284.0% during the first quarter. Victory Capital Management Inc. now owns 322,718 shares of the biotechnology company’s stock worth $37,984,000 after purchasing an additional 299,400 shares during the last quarter. TD Asset Management Inc. lifted its stake in Ascendis Pharma A/S by 14.0% during the first quarter. TD Asset Management Inc. now owns 87,368 shares of the biotechnology company’s stock worth $10,283,000 after purchasing an additional 10,696 shares during the last quarter. Finally, Artisan Partners Limited Partnership lifted its stake in Ascendis Pharma A/S by 208.2% during the first quarter. Artisan Partners Limited Partnership now owns 1,131,107 shares of the biotechnology company’s stock worth $133,131,000 after purchasing an additional 764,160 shares during the last quarter.

ASND has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their price target on Ascendis Pharma A/S from $143.00 to $152.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. Wedbush reissued a “buy” rating and issued a $223.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, June 28th. Canaccord Genuity boosted their target price on Ascendis Pharma A/S from $133.00 to $144.00 and gave the company a “buy” rating in a research note on Friday, May 31st. Zacks Investment Research raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Tuesday, August 27th. Finally, BidaskClub lowered Ascendis Pharma A/S from a “sell” rating to a “strong sell” rating in a research note on Thursday. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $153.29.



Shares of NASDAQ ASND traded down $1.75 during midday trading on Friday, reaching $102.82. The company had a trading volume of 19,728 shares, compared to its average volume of 202,170. Ascendis Pharma A/S has a one year low of $53.21 and a one year high of $133.96. The company has a quick ratio of 11.59, a current ratio of 11.59 and a debt-to-equity ratio of 0.05. The firm’s fifty day moving average price is $113.12 and its 200-day moving average price is $115.49. The stock has a market cap of $4.44 billion, a PE ratio of -27.55 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, August 28th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.08). Ascendis Pharma A/S had a negative net margin of 932.52% and a negative return on equity of 35.99%. The company had revenue of $3.61 million during the quarter, compared to the consensus estimate of $0.68 million. As a group, equities research analysts expect that Ascendis Pharma A/S will post -5.31 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Read More: Understanding Options Trading

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.